Hepatitis C viral dynamics: Basic concept and clinical significance

Journal of Clinical Virology

Volumn 25, Issue SUPPL. 3, 2002, Pages 31-39

  Jessner, Wolfgang ^a   Watkins Riedel, Thomas ^b   Formann, Elisabeth ^a   Steindl Munda, Petra ^a   Ferenci, Peter ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Chronic infection; Hepatitis C virus; Induction therapy; Pegylated interferon alpha; Treatment response; Viral dynamics

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; PEGINTERFERON ALPHA2A; REBETRON; RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN; VIRUS RNA;

CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ASSAY; TREATMENT OUTCOME; VIRION; VIRUS LOAD;

EID: 0036898952     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1386-6532(02)00194-4     Document Type: Conference Paper

References (54)

1. Bekkering F.C., Brouwer J.T., Hansen B.E., Schalm S.W. Hepatitis C viral kinetics is difficult to treat patients receiving high dose interferon and ribavirin. J. Hepatol. 34:2001;435-440.
2. Bekkering F.C., Stalgis C., McHutchison J.G., Brouwer J.T., Perelson A.S. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. Hepatology. 33:2001;419-423.
3. Beld M., Sentjens R., Rebers S., Weegink C., Weel J., Sol C., Boom R. Performance of the New Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: Conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, assay. J. Clin. Microbiol. 40:2002;788-793.
4. Benjamin R.J. Nucleic acid testing: Update and applications. Semin. Hematol. 38:(4 Suppl. 9):2001;11-16.
5. Bergmann C.C., Layden J.E., Levy-Drummer R.S., Layden T.J., Haagmans B.L., Neumann A.U. Clinical implications of a new tri-phasic model for hepatitis C viral kinetics during IFN-alfa therapy. Hepatology. 34:2001;345A.
6. Bjoro K., Bell H., Myrvang B., Skaug K., Raknerud N., Sandvei P., Storseth S., Ritland S., Lund-Tonnesen S., Bucher A., Hellum K.B. Effect of interferon-alfa induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection. Scand. J. Gastroenterol. 3:2002;344-349.
7. Buti M., Sanchez-Avila F., Lurie Y., Stalgis C., Valdes A., Martell M., Esteban R. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology. 35:2002;930-936.
8. Carithers R.L., Zeuzem S., Manns M.P., McHutchison J.G., Perillo R.P., Bailey R., Ling M.H., Cohard-Radice M., Albrecht J.K. Multicenter, randomized, controlled trial comparing high dose daily induction interferon plus ribavirin versus standard interferon alfa-2b plus ribavirin. Hepatology. 32:2000;317A.
9. Carlsson T., Reichard O., Weiland O. Hepatitis C virus kinetics during induction and standard 3 times a week interferon-alpha therapy. Scand. J. Infect. Dis. 33:2001;838-842.
10. Diago M., Suarez D., Garcia-Villarreal L., Castro A., Dominguez A., Pardo M., del Olmo J.A., Perez-Hernandez F., Aguilar J., Quiroga J.A., Carreno V. Multicenter randomized study comparing initial daily induction with high dose lymphoblastoid interferon vs. standard interferon treatment for chronic hepatitis C. J. Med. Virol. 64:2001;460-465.
11. Ferenci P. Have we achieved the optimal dosing of interferon in hepatitis C. Viral. Hepatitis Rev. 5:1999;229-245.
12. Ferenci P., Brunner H., Nachbaur K., Datz C., Gschwantler M., Hofer H., Stauber R., Hackl F., Jessner W., Rosenbeiger M., Munda-Steindl P., Hegenbarth K., Gangl A., Vogel W. Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology. 34:2001;1006-1011.
13. Ferenci P., Shiffman M.L., Fried M., Sulkowski M.S., Häussinger D., Zarski J.P., Goncales F., Jensen D.M., Bonino F., Dhumeaux D., Blotner S., Hoffman J., Oliveto J. Early prediction of response to 40 kDa peginterferon alfa-2a (PEGASYS) plus ribavirin (RBV) in patients with chronic hepatitis C (CHC). Hepatology. 34:2001;351A.
14. Ferenci P, Jessner W, Hackl F, Gschwantler M, Brunner H, Hellmich B, Laferl H, Stauber R, Hubmann R, Datz C. Prediction of early virologic response to treatment with 40 kDa Pegylated (PEG)-interferon alfa2a/ribavirin in patients with chronic hepatitis C (genotype 1). DDW 2002 (Abstract).
15. Formann E., Jessner W., Bennet L., Ferenci P. Twice weekly administration of PegIntron improves viral kinetics in patients with chronic hepatitis C genotype 1. Hepatology. 36:2002;288A.
16. Gerken G., Rothaar T., Rumi M.G., Soffredini R., Trippler M., Blunk M.J., Butcher A., Soviero S., Colucci G. Performance of the COBAS AMPLICOR HCV MONITOR test, version 2.0, an automated reverse transcription-PCR quantitative system for hepatitis C virus load determination. J. Clin. Microbiol. 38:2000;2210-2214.
17. Germer J.J., Heimgartner P.J., Ilstrup D.M., Harmsen W.S., Jenkins G.D., Patel R. Comparative evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0, and COBAS AMPLICOR HCV MONITOR version 2.0 assays for quantification of hepatitis C virus RNA in serum. J. Clin. Microbiol. 40:2002;495-500.
18. Glue P., Rouzier-Panis R., Raffanel C., Sabo R., Gupta S.K., Salfi M., Jacobs S., Clement R.P. A dose-ranging study of Pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology. 32:2000;647-653.
19. Gonzalez H.J., Ho S.B., Gross J.B., Peine C., McKee D., Smith T. Efficacy of daily induction dosing (5 MU 4 weeks) vs standard thrice weekly dosing of interferon-alpha2B for initial treatment of chronic hepatitis C. Dig. Dis. Sci. 47:2002;784-792.
20. Hadziyannis A.S., Papaioannou C., Spanou F., Manesis E.K., Hadziyannis S.J. Induction interferon therapy in naive patients with chronic hepatitis C: Increased end-of-treatment virologic responses but absence of long-term benefit. Aliment Pharmacol. Ther. 15:2001;551-557.
21. Heathcote J., Shiffman M.L., Cooksley G.E., Dusheiko G.M., Lee S.S., Balart L., Reindollar R., Reddy R.K., Wright T.L., Lin A., Hoffman J., De Pamphilis J. PegInterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 343:2000;1673-1680.
22. Hofer H, Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-Munda P, Gangl A, Ferenci P. Spontaneous Viral Clearance in Patients with Acute Hepatitis C can be Predicted by Repeated Measurements of Serum Viral Load, in press.
23. Jessner W., Gschwantler M., Steindl-Munda P., Hofer H., Watkins-Riedel T., Wrba F., Mueller C., Gangl A., Ferenci P. Primary interferon resistance and treatment response in chronic hepatitis C infection: A pilot study. Lancet. 358:2001;1241-1242.
24. Jessner W., Gschwantler M., Watkins-Riedel T., Steindl-Munda P., Mueller C., Ferenci P. Primary IFN-resistance in chronic heaptitis C virus genotype 4 infection. J. Hepatol. 36:2002;113A.
25. Jessner W, Stauber R, Hackl F, Datz C, Watkins-Riedel T, Hofer H, Gangl A, Kessler H, Ferenci P. Early viral kinetics on treatment with Pegylated interferon alpha2a in chronic hepatitis C virus genotype 1 infection. J. Viral. Hepatitis, in press.
26. Jungkind D. Automation of laboratory testing for infectious diseases using the polymerase chain reaction - our past, our present, our future. J. Clin. Virol. 20:2001;1-6.
27. Konnick E.Q., Erali M., Ashwood E.R., Hillyard D.R. Performance characteristics of the COBAS Amplicor hepatitis C virus HCV monitor, version 2.0, international unit assay and the National Genetics Institute HCV superquant assay. J. Clin. Microbiol. 40:2002;768-773.
28. Lam N.P., Neumann A.U., Gretch D.R., Wiley T.E., Perelson A.S., Layden T.J. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology. 26:1997;226-231.
29. Layden J.E., Layden T.J. How can mathematics help us understand HCV? Gastroenterology. 120:2001;1546-1548.
30. Layden JE, Layden TJ, Levi-Drummer R, Reddy KR, Poulakos J, Neumann AU. Early viral kinetics of HCV-predicting treatment response after only 24 hours. Digestive Disease Week Program Book 2001;A30.
31. Lee S.S., Heathcote J., Reddy R.K., Zeuzem S., Fried M., Wright T.L., Pockros P.J., Haussinger D., Smith C.I., Lin A., Pappas S.C. Prognostic factors and early predictability of sustained viral response with Peginterferon alfa-2a. J. Hepatol. 37:2002;500-506.
32. Lee S.S., Heathcote J., Reddy R.K., Zeuzem S., Fried M., Wright T.L. Pockros PJ, Haussinger D, Smith CI, Lin A, Pappas SC. Prognostic factors and early predictability of sustained viral response with Peginterferon alfa-2a. J. Hepatol. 37:2002;500-506.
33. Lindsay K.L., Trepo C., Heintges T., Shiffman M.L., Gordon S.C., Hoefs J., Schiff E.R., Goodman Z.D., Laughlin M., Yao R., Albrecht J.K. A randomized, double-blind trial comparing Pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 34:2001;395-403.
34. Mangia A., Santoro R., Piatelli M., Leandro G., Minerva N., Annese M., Bacca D., Spirito F., Carretta V., Ventraella F., Cela M., Andriulli A. High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis. J. Hepatol. 37:2002;109-116.
35. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M.L., Reindollar R., Goodman Z.D., Koury K., Ling M.H., Albrecht J.K. PegInterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 358:2001;958-965.
36. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling M.H., Cort S., Albrecht J.K. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339:1998;1485-1492.
37. McHutchison J.G., Shad J.A., Gordon S.C., Morgan T.R., Ling M.H., Garaud J.J., Albrecht J.K., Dienstag J.L. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy. J. Viral. Hepat. 8:2001;414-420.
38. Modi M.W., Fried M., Reindollar R.W., Rustgi V.R., Kenny R., Wright T.L., Gibas A., Martin N.E. The pharmacokinetic behavior of pegylated (40 kDa) interferon alfa-2a (pegasys) in chronic hepatitis C patients after multiple dosing. Hepatology. 32:2000;394A.
39. Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., Layden T.J., Perelson A. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science. 282:1998;103-107.
40. Neumann A.U., Lam N.P., Dahari H., Davidian M., Wiley T.E., Mika B.P., Perelson A.S., Layden T.J. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J. Infect. Dis. 182:2000;28-35.
41. Neumann A.U., Layden T.J., Reddy K.R., Levy-Drummer R.S., Poulakos J. The 2nd phase slope of HCV decline is highly predictive of sustained virologic response (SVR) following consensus interferon (INFERGEN) treatment for chronic hepatitis C and is determined by genotype but not by dose. Hepatology. 32:2000;356A.
42. Nguyen T.T., Sedghi-Vaziri A., Wilkes L.B., Mondala T., Pockros P.J., Lindsay K.L., McHutchison J.G. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J. Viral. Hepat. 3:1996;75-78.
43. Pape G.R., Gerlach T.J., Diepolder H.M., Gruner N., Jung M., Santantonio T. Role of the specific T-cell response for clearance and control of hepatitis C virus. J. Viral. Hepat. 6:1999;S36-S40.
44. Pawlotsky J.M. Hepatitis C virus resistance to antiviral therapy. Hepatology. 32:2000;889-896.
45. Pawlotsky J.M., Bouvier-Alias M., Hezode C., Darthuy F., Remire J., Dhumeaux D. Standardization of hepatitis C virus RNA quantification. Hepatology. 32:2000;654-659.
46. Ramratnam B., Bonhoeffer S., Binley J., Hurley A., Zhang L., Mittler J.E., Markowitz M., Moore J.P., Perelson A.S., Ho D.D. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet. 354:1999;1782-1785.
47. Rosen H.R., Ribeiro R.R., Weinberger L., Wolf S., Chung M., Gretch D.R., Perelson A.S. Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy. J. Hepatol. 37:2002;124-130.
48. Stark G.R., Kerr I.M., Williams B.R.G., Silverman R.H., Schreiber R.D. How cells respond to interferons. Annu. Rev. Biochem. 67:1998;227-264.
49. Steindl-Munda P., Jessner W., Vogel W., Datz C., Brunner H., Stauber R., Ferenci P. High dose interferon induction therapy does not improve response to combination therapy in relapsers and nonresponders to previous interferon monotherapy. J. Hepatol. 34:2001;166A.
50. Van Vlierberghe H., Leroux-Roels G., Burgeois N., Nevens F., Colle I., Henrion J., Delwaide J., Horsmans Y., Brenard R., Michielsen P., Robaeys G., Bruckers L. Daily induction combination treatment with alfa2b interferon or standard combination treatment in naive chronic hepatitis C patients: A controlled multicenter trial. Hepatology. 32:2000;364A.
51. Zeuzem S., Schmidt J.M., Lee J.-H., Rüster B., Roth W.K. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology. 23:1996;366-371.
52. Zeuzem S., Schmidt J.M., Lee J.-H., Wagner M., Teuber G., Roth W.K. Hepatitis C virus dynamics in vivo: Effect of ribavirin and interferon alfa on viral turnover. Hepatology. 28:1998;245-252.
53. Zeuzem S., Feinmann S.V., Rasenack J., Heathcote J., Lai M.Y., Gane E., O'Grady J., Reichen J., Diago M., Lin A., Hoffman J., Brunda M.J. PegInterferon alfa-2a in patients with chronic hepatitis C. N. Engl. J. Med. 343:2000;1666-1672.
54. Zeuzem S., Herrmann E., Lee J.-H., Fricke J., Neumann A.U., Modi M., Colucci G., Roth W.K. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology. 120:2001;1438-1447.